Comparative cardioprotective effects of carvedilol versus atenolol in a rat model of cardiorenal syndrome type 4
- 16 August 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in Naunyn-Schmiedebergs Archiv für experimentelle Pathologie und Pharmakologie
- Vol. 394 (10), 2117-2128
- https://doi.org/10.1007/s00210-021-02130-1
Abstract
The incidence of chronic kidney disease is escalating; cardiorenal syndrome (CRS) type 4 is gaining a major health concern causing significant morbidity and mortality, putting major burdens on the healthcare system. This study was designed to compare the cardioprotective effects of carvedilol versus atenolol against CRS type 4 induced by subtotal 5/6 nephrectomy in rats and to explore the underlying mechanisms. Immediately after surgery, carvedilol (20 mg/kg/day) or atenolol (20 mg/kg/day) was added to drinking water for 10 weeks. Carvedilol was more effective than atenolol in improving kidney functions, decreasing elevated blood pressures, attenuating cardiac hypertrophy, reducing serum brain natriuretic peptide, and diminished cardiac fibrous tissue deposition. However, carvedilol was equivalent to atenolol in modulating β1-adrenergic receptors (β1ARs) and cardiac diacylglycerol (DAG) signaling, but carvedilol was superior in modulating β-arrestin2, phosphatidyl inositol 4,5 bisphosphates (PIP2), and caspase 3 levels. Carvedilol has superior cardioprotective effects than atenolol in a rat model of CRS type 4. These protective effects are mediated through modulating cardiac β1ARs/β-arrestin2/PIP2/DAG as well as abating cardiac apoptotic signaling pathways (caspase3/pS473 protein kinase B (Akt)).Keywords
This publication has 60 references indexed in Scilit:
- Benefits of blockers in patients with heart failure and reduced ejection fraction: network meta-analysisBMJ, 2013
- Diacylglycerol Activation of Protein Kinase Cε and Hepatic Insulin ResistanceCell Metabolism, 2012
- β-Arrestin: A signaling molecule and potential therapeutic target for heart failureJournal of Molecular and Cellular Cardiology, 2011
- p53 directly suppresses BNIP3 expression to protect against hypoxia-induced cell deathThe EMBO Journal, 2011
- Cardiorenal Syndrome Type 4—Cardiovascular Disease in Patients with Chronic Kidney Disease: Epidemiology, Pathogenesis, and ManagementInternational Journal of Nephrology, 2011
- Cardio-renal syndromes: report from the consensus conference of the Acute Dialysis Quality InitiativeEuropean Heart Journal, 2009
- β-Blockers alprenolol and carvedilol stimulate β-arrestin-mediated EGFR transactivationProceedings of the National Academy of Sciences of the United States of America, 2008
- A unique mechanism of β-blocker action: Carvedilol stimulates β-arrestin signalingProceedings of the National Academy of Sciences of the United States of America, 2007
- Chronic Kidney Disease and the Risks of Death, Cardiovascular Events, and HospitalizationThe New England Journal of Medicine, 2004
- Carvedilol increases two-year survivalin dialysis patients with dilated cardiomyopathy: A prospective, placebo-controlled trialJournal of Invasive Cardiology, 2003